Marker in Prostate Cancer Fails to Predict Response to PARP Inhibition

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

This video examines clinical and genomics data from the NCI 9012 trial, which studied abiraterone combined with a PARP inhibitor in patients with metastatic castration-resistant prostate cancer.

In this video, Maha H. Hussain, MD, of the Lurie Cancer Center in Chicago, discusses clinical and genomics data from the NCI 9012 trial, which studied abiraterone and prednisone with or without the PARP inhibitor veliparib in patients with metastatic castration-resistant prostate cancer (mCRPC).

Hussain reports that ETS fusion–positive tumors did not predict response to treatment, but also that the design of the trial allowed investigators to discover a surprise finding among patients with DNA repair gene–deficient tumors.

The study results were presented (abstract 5001) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.

Recent Videos
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Related Content
Social Determinants of Health Negatively Affected Endometrial Cancer Diagnosis

Social Determinants of Health Negatively Affected Endometrial Cancer Diagnosis

Tim Cortese
March 19th 2025
Article

Factors such as language spoken, social vulnerability index characteristics, and insurance type were found to alter endometrial cancer diagnoses and led to worse outcomes.

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Rahul Banerjee, MD, FACP;Shernan Holtan, MD
March 3rd 2025
Podcast

Shernan Holtan, MD, and Rahul Banerjee, MD, FACP, discussed various trials of significance shared as posters and presentations at the 2025 Tandem Meeting.

Certain subpopulations experienced significantly poorer outcomes in 2020, highlighting concerns regarding access to care.

Vulvar Cancer Survival Discrepancies Seen in Year 1 of COVID-19 Pandemic

Roman Fabbricatore
March 19th 2025
Article

Certain subpopulations experienced significantly poorer outcomes in 2020, highlighting concerns regarding access to care.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Patients who had recurrence in the radiation field experienced similar responses vs those with recurrence outside the radiation field.

Immunotherapy Sustains Responses in Radiated Endometrial/Cervical Cancer

Roman Fabbricatore
March 18th 2025
Article

Patients who had recurrence in the radiation field experienced similar responses vs those with recurrence outside the radiation field.

Socioeconomic or racial disparities may contribute to unchanged overall survival among certain patients with metastatic uterine cancer.

Uterine Cancer Survival Rates Have Improved Despite Higher Mortality Risks

Russ Conroy
March 18th 2025
Article

Socioeconomic or racial disparities may contribute to unchanged overall survival among certain patients with metastatic uterine cancer.